<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372954</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-Retro</org_study_id>
    <nct_id>NCT03372954</nct_id>
  </id_info>
  <brief_title>Retrograde Application of Bone Marrow Aspirate Concentrate</brief_title>
  <acronym>Retro</acronym>
  <official_title>Retrograde Application of Bone Marrow Aspirate Concentrate (BMAC) Through Coronary Sinus in Patients With Congestive Heart Failure of Ischemic Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our prospective randomised study is to assess the efficacy of the retrograde
      application of non-selected bone marrow autologous cells concentrate (BMAC) in patients with
      heart failure with reduced ejection fraction of left ventricle (HFREF) of ischemic aetiology.
      The evaluated preparation is concentrated BMAC, obtained using Harvest SmartPReP2 technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our assumption is that non-selected BMAC administrations will lead to improvements in the
      left ventricular ejection fraction (LV EF), the left ventricular end-systolic and
      end-diastolic diameters and volumes (measured with magnetic resonance imaging) compared to
      standard heart failure therapy.

      Furthermore, it will be associated with improved exercise tolerance in the six-minute
      corridor walk test and an improvement in the life quality of patients without increasing the
      incidence of severe ventricular arrythmias.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end-systolic diameter (LVESd)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-systolic diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-systolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-diastolic diameter (LVEDd)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-diastolic diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>12 month</time_frame>
    <description>Left ventricular end-diastolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ejection fraction of left ventricle (EF LV)</measure>
    <time_frame>12 month</time_frame>
    <description>ejection fraction of left ventricle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>corridor walk test</measure>
    <time_frame>12 month</time_frame>
    <description>walk distance in 6 min corridor walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>12 month</time_frame>
    <description>Quality of patients´ life using the Minnesota questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Bone marrow autologous cells concentrate (BMAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>retrograde administration on non-selected BMAC via coronary sinus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard treatment o heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMAC</intervention_name>
    <description>retrograde administration on non-selected BMAC via coronary sinus</description>
    <arm_group_label>Bone marrow autologous cells concentrate (BMAC)</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic heart failure and left ventricular ejection fraction ≤ 40% with
             coronary artery disease and with symptoms of heart failure in the NYHA class ≥ 3 on
             standard heart failure therapy for 3 months and in a stabilised state for at least 1
             month

          -  Age ≥18 years

          -  Informed, written consent by the patient

          -  Ability to comply fully with the study protocol

          -  Negative pregnancy test (and effective contraception) in women with childbearing
             potential

        Exclusion Criteria:

          -  Previous bone marrow disease (especially myelodysplastic syndrome or non-Hodgkin's
             lymphoma)

          -  Acute myocardial infarction ˂ 1 week

          -  Active infection or antibiotics treatment ˂ 1 week

          -  Previous malingant ventricular arrhythmias without cardioverter-defibrilator (ICD)
             implantation

          -  Anemia (HTC≤28%), leukocythosis (≥ 14.000/mm3) or thrombocytopenia (≤50.000/mm3)

          -  Previous bleeding diathesis

          -  Need for hematopoietic growth factor treatment (e.g. erythropoetin, G-CSF)

          -  Impossibility of aspiration 240ml of bone marrow

          -  Hepathopathy or cirrhosis (bilirubin, ALT or AST ≥ 2,5x upper limit of normal)

          -  Terminal renal insufficiency or haemodyalysis

          -  Uncontrolled hypertension

          -  Need for high dose (&gt; 7.5mg/day) corticotherapy within the next 6 months

          -  Inability to stop anticoagulation therapy (&gt;72 hours) before bone marrow aspiration

          -  Known malignancies requiring actino or chemotherapy, or previous actinotherapy

          -  Patients with a BMI &gt;40

          -  Known allergy to contrast agents

          -  Other comorbidities with a life expectancy of 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

